Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price32.85 USD
Fair value65.70
Ethical score87.2/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-02Read Markup32.85+0.0% to today ✓
2026-08-26Read Distribution26.28+25.0% to today
2026-07-02Read Markup29.46+11.5% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cue Biopharma, Inc. holds its Markup at $32.85. Consolidating, no directional conviction, held for 42 days.
As held on the ledger · 2026-09-24
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 42 days
Price at the screen
$32.85
Valuation
N/A trailing · -68.44 forward price to earnings
Values screen
PASS· score 87.2
Beta
2.46
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.38%
Below 33%
Interest-bearing debt is just 4.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
29.45%
Below 33%
Cash held in interest-bearing accounts and securities is 29.5% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Cue Biopharma, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 4%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 100% discount to our $65.70 fair value, 166.70% revenue growth.
Fair value range in USD, drawn from the 2026-09-24 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 3 covering, consensus Strong Buy. The average target sits +153% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-24 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it is worth knowing
A quality business. It trades close to our $65.70 fair value, so the easy discount is gone; you would be paying up for the quality.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CUE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup · changed$32.85+25.0%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 25.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading oversold. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it strong buy, with a mean price target of $115. Since the last review it entered the Titan Ethical 500.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading oversold. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it strong buy, with a mean price target of $115.
2026-07-25Markup$31.16+5.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it strong buy, with a mean price target of $115.
2026-07-18Markup$29.46+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (1 analysts) rates it strong buy, with a mean price target of $115.
2026-07-03Markup$29.46+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$29.46Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.